参考文献 [1] Briere F, Bendriss-Vermare N, DelaleT, et al. Origin and filiation of human plasmacytoid dendritic cells. Hum Immunol, 2002,63(12): 1081–1093. [2] Rutella S, Danese S, Leone G, et al. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood, 2006, 108(5): 1435–1440. [3] Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med, 2006, 203(4): 871–881. [4] Mahnke K, Ring S, Johnson TS, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4(+)CD25(+) regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol, 2007, 37(8): 2117–2126. [5] Buisson S, Triebel F. LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology, 2005, 114(3): 369–374. [6] Forster R, Davalos-Misslitz AC, Rot A, et al. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol, 2008, 8(5): 362–371. [7] Min SY, Park KS, Cho ML, et al. Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in Peyer’s patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum, 2006, 54(3): 887–898. [8] Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cel differentiation by IFN-alpha in systemiclupus erythematosus. Science, 2001, 294(5546): 1540–1543. [9] Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA , 2005, 102: (52): 19057–19062. [10] Dunn GP, old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol, 2004, 22: 329-360. [11] Luftl M, Feng A, Licha E, et al. Dendritic cells and apoptosis in mycosis fungoides. British Journal of Dermatology, 2002, 147(6): 1171–1179. [12] Schlapbach C, Ochsenbein A , Kaelin U, et al. High numbers of DC-SIGN plus dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol, 2010, 62(6): 995-1004. [13] Steinbrink K, Jonuleit H, Muller G, et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood, 1999, 93(5): 1634–1642. [14] Wang TH, Niu GL, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med, 2004, 10(1): 48–54. [15] Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res , 2001, 23(2-3): 263–272.